References

How to Subscribe
MLS & MLT Comprehensive CE Package
Includes 185 CE courses, most popular		$109Add to cart
Pick Your Courses
Up to 8 CE hours		$55Add to cart
Individual course$25Add to cart
The page below is a sample from the LabCE course Case Studies in Hematology - Malignant WBC Disorders. Access the complete course and earn ASCLS P.A.C.E.-approved continuing education credits by subscribing online.

Learn more about Case Studies in Hematology - Malignant WBC Disorders (online CE course)
References

Barbui, T., Thiele, J., Ferrari, A., Vannucchi, A,. & Tefferi, A. (2022). The new WHO classification for essential thrombocythemia calls for revision of available evidences. Blood Cancer Journal, 10(2):1-6. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7042222/.
Briere, J. (2007). Essential thrombocythemia. Orphanet Journal of Rare Diseases, 2(3):1-17. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1781427/.
Davis, J., & Sandler, E. (2015). Acute precursor B-cell lymphoblastic leukemia in a 1-year-old white male: Diagnostic evaluation and flow cytometric analysis. Laboratory Medicine, 46(3):82-87. https://academic.oup.com/labmed/article/46/3/e82/2657965.
Dotson, J., & Lebowicz, Y. Myelodysplastic syndrome. National Library of Medicine. https://www.ncbi.nlm.nih.gov/books/NBK534126/.
Lai, A. (2021). What are the diagnostic criteria for essential thrombocytosis? Medscape. https://www.medscape.com/answers/206697-184824/what-are-the-diagnostic-criteria-for-essential-thrombocytosis-primary-thrombocythemia.
Leonard, J., Martin, P., & Robot, G. (2017). Practical implications of the 2016 revision of the World Health Organization classification of lymphoid and myeloid neoplasms and acute leukemia. Journal of Clinical Oncology, 25(23):2708-2715.
Leukemia and Lymphoma Society. (2023). Signs and symptoms. www.lls.org/myeloproliferative-neoplasms/essential-thrombocythemia/signs-and-symptoms.
McPherson, R., & Pincus, M. (2017). Henry's clinical diagnosis and management by laboratory methods. Elsevier.
National Cancer Institute. (2022). Childhood acute lymphoblastic leukemia treatment (PDQ). https://www.cancer.gov/types/leukemia/hp/child-all-treatment-pdq#_1.
Rajan, A., & Rajkumar, S. (2015). Interpretation of cytogenetic results in multiple myeloma for clinical practice. Blood Cancer Journal, 92(5):1-7. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4635200/pdf/bcj201592a.pdf.
Rashed, W., Hamad, A., Saad, A., & Shoddy, K. (2019). MicroRNA as a diagnostic biomarker in childhood acute lymphoblastic leukemia; systematic review, meta-analysis and recommendations. Critical Reviews Oncology Hematology, 10(136):70-78.
Turgeon, M. (2018). Clinical hematology theory and procedures. Wolters Kluwer.
Vora, A. (2017). Childhood acute lymphoblastic leukemia. Springer International.
Yogarajah, M., Nguyen, P., He, R., et al. (2019). Discrepancy of blast percentage between the bone marrow aspirate and flow cytometry and its impact on survival outcomes in patients with myelodysplastic syndromes excess blast. Blood, 134(1):1-3.